These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 22229564)

  • 21. Obesity and the polycystic ovary syndrome.
    Martínez-Bermejo E; Luque-Ramírez M; Escobar-Morreale HF
    Minerva Endocrinol; 2007 Sep; 32(3):129-40. PubMed ID: 17912153
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Association Between Bisphenol A and Polycystic Ovarian Syndrome: A Case-Control Study.
    Hossein Rashidi B; Amanlou M; Behrouzi Lak T; Ghazizadeh M; Haghollahi F; Bagheri M; Eslami B
    Acta Med Iran; 2017 Dec; 55(12):759-764. PubMed ID: 29373882
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Environmental toxin exposure in polycystic ovary syndrome women and possible ovarian neoplastic repercussion.
    Soave I; Occhiali T; Assorgi C; Marci R; Caserta D
    Curr Med Res Opin; 2020 Apr; 36(4):693-703. PubMed ID: 32046531
    [No Abstract]   [Full Text] [Related]  

  • 24. Metabolic consequences of obesity and insulin resistance in polycystic ovary syndrome: diagnostic and methodological challenges.
    Jeanes YM; Reeves S
    Nutr Res Rev; 2017 Jun; 30(1):97-105. PubMed ID: 28222828
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Polycystic ovary syndrome--phenotypes and diagnosis.
    Christakou C; Diamanti-Kandarakis E
    Scand J Clin Lab Invest Suppl; 2014; 244():18-22; discussion 21. PubMed ID: 25083888
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Body composition and polycystic ovary syndrome].
    Zabuliene L; Tutkuviene J
    Medicina (Kaunas); 2010; 46(2):142-57. PubMed ID: 20440089
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The association between the environmental endocrine disruptor bisphenol A and polycystic ovary syndrome: a systematic review and meta-analysis.
    Hu Y; Wen S; Yuan D; Peng L; Zeng R; Yang Z; Liu Q; Xu L; Kang D
    Gynecol Endocrinol; 2018 May; 34(5):370-377. PubMed ID: 29191127
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Can environmental pollutant bisphenol A increase metabolic risk in polycystic ovary syndrome?
    Milanović M; Milošević N; Sudji J; Stojanoski S; Atanacković Krstonošić M; Bjelica A; Milić N; Medić Stojanoska M
    Clin Chim Acta; 2020 Aug; 507():257-263. PubMed ID: 32387634
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Contribution of Advanced Glycation End Products to PCOS Key Elements: A Narrative Review.
    Mouanness M; Nava H; Dagher C; Merhi Z
    Nutrients; 2022 Aug; 14(17):. PubMed ID: 36079834
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The role of obesity in the development of polycystic ovary syndrome.
    Motta AB
    Curr Pharm Des; 2012; 18(17):2482-91. PubMed ID: 22376149
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Soy but not bisphenol A (BPA) induces hallmarks of polycystic ovary syndrome (PCOS) and related metabolic co-morbidities in rats.
    Patisaul HB; Mabrey N; Adewale HB; Sullivan AW
    Reprod Toxicol; 2014 Nov; 49():209-18. PubMed ID: 25242113
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Polycystic ovary syndrome in the Indian Subcontinent.
    Allahbadia GN; Merchant R
    Semin Reprod Med; 2008 Jan; 26(1):22-34. PubMed ID: 18181079
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Introduction: Determinants of polycystic ovary syndrome.
    Azziz R
    Fertil Steril; 2016 Jul; 106(1):4-5. PubMed ID: 27238627
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Effects of eight environmental endocrine disruptors on insulin resistance in patients with polycystic ovary syndrome: a preliminary investigation].
    Li TT; Xu LZ; Chen YH; Deng HM; Liang CY; Liu Y; Liu XF; Zhang J; Kang DY; Qiu DS; Han DW; Hu R
    Nan Fang Yi Ke Da Xue Xue Bao; 2011 Oct; 31(10):1753-6. PubMed ID: 22027783
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Characterization of reproductive, metabolic, and endocrine features of polycystic ovary syndrome in female hyperandrogenic mouse models.
    Caldwell AS; Middleton LJ; Jimenez M; Desai R; McMahon AC; Allan CM; Handelsman DJ; Walters KA
    Endocrinology; 2014 Aug; 155(8):3146-59. PubMed ID: 24877633
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Polycystic ovary syndrome: a multifaceted disease from adolescence to adult age.
    Pasquali R; Gambineri A
    Ann N Y Acad Sci; 2006 Dec; 1092():158-74. PubMed ID: 17308142
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Insulin resistance and endocrine characteristics of the different phenotypes of polycystic ovary syndrome: a prospective study.
    Panidis D; Tziomalos K; Misichronis G; Papadakis E; Betsas G; Katsikis I; Macut D
    Hum Reprod; 2012 Feb; 27(2):541-9. PubMed ID: 22144419
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Review: fetal programming of polycystic ovary syndrome by androgen excess: evidence from experimental, clinical, and genetic association studies.
    Xita N; Tsatsoulis A
    J Clin Endocrinol Metab; 2006 May; 91(5):1660-6. PubMed ID: 16522691
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Changes in the PCOS phenotype with age.
    Hsu MI
    Steroids; 2013 Aug; 78(8):761-6. PubMed ID: 23624031
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Type 2 diabetes and the polycystic ovary syndrome.
    Pelusi B; Gambineri A; Pasquali R
    Minerva Ginecol; 2004 Feb; 56(1):41-51. PubMed ID: 14973409
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.